After 5 Years as Head, Dr. Broder Plans to Resign His Post at NCI
WASHINGTON--Samuel Broder, MD, head of the National Cancer Institute (NCI) for the past 5 years, says that he will resign his post in April of this year. He will join IVAX Corporation (Miami), a manufacturer of generic drugs and IV drug delivery devices, where he plans to work on developing new drugs.
WASHINGTON--Samuel Broder, MD, head of the National Cancer Institute(NCI) for the past 5 years, says that he will resign his postin April of this year. He will join IVAX Corporation (Miami),a manufacturer of generic drugs and IV drug delivery devices,where he plans to work on developing new drugs.
Dr. Broder first joined the NCI in 1972 as a researcher. He wasthe leader of a group that discovered the therapeutic benefitsof the antiretroviral agent zidovudine (Retrovir, AZT) in 1985.
FDA Approves Encorafenib/Cetuximab Plus mFOLFOX6 for Advanced BRAF V600E+ CRC
December 20th 2024The FDA has granted accelerated approval to encorafenib in combination with cetuximab and mFOLFOX6 for patients with metastatic colorectal cancer with a BRAF V600E mutation, as detected by an FDA-approved test.
